Naval Daver MDAssociate Professor, Leukemia Department, MD Anderson Cancer Center, Houston, TX
Dr Naval Daver is an Associate Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center. He completed his medical school from Grant Medical College and Sir J J group of Hospitals, Mumbai followed by a residency and fellowship in hematology-oncology from Baylor College of Medicine. He is a clinical investigator with a focus on molecular and immune therapies in AML and Myelofibrosis and is principal investigator on >25 ongoing institutional, national and international clinical trials in these diseases. These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune and cytotoxic agents, and identifying and overcoming mechanism of resistance. He is especially interested in developing monoclonal and bispecific antibodies, immune checkpoint and vaccine based approaches, as well as targeted and apoptotic therapies in AML and is leading a number of these trials at MDACC. Dr Daver has published >200 peer-reviewed manuscripts and is on the editorial board of numerous hematology specific journals. He has also authored numerous abstracts at national and international conferences.
Dr. Daver’s List of Financial Disclosures: Pfizer, Otsuka, Novartis, BMS, Incyte, Sunesis, Karyopharm, Jazz, Daichi-Sankyo, Abbvie, Glycomimetics, Servier, Genentech, Covance, Immunogen, NOHLA Therapeutics, Agios
Research Funding: Pfizer, BMS, Novartis, Daiichi-Sankyo, Karyopharm, Incyte, Abbvie, Sunesis, Servier, Genentech, NOHLA, Glycomimetics, Immunogen
Advisory/Consulting: Pfizer, Novartis, BMS, Otsuka, Celgene, Incyte, Jazz, Karyopharm, Sunesis, Immunogen, Abbvie,Astellas, Daiichi-Sankyo, Agios
Dr. Daver’s List of Financial Disclosures
Honararia: BMS, Jazz, Novartis, Incyte, Otsuka, Immunogen, Pfizer, Astellas, Abbvie